Engineering antibody fragments: replicating the immune system and beyond

Since genetic engineering of humanized murine monoclonal antibodies was fi rst demonstrated over two decades ago, antibody engineering technologies have evolved based upon an increasing understanding of the mechanisms involved in antibody generation in vivo, and a constant search for alternative rou...

Full description

Autores:: García-Quiroz, F. (Felipe)
Sinclair, M. (Michael)

Tipo de recurso:: Article of journal

Fecha de publicación:: 2010

Institución:: Universidad EIA .

Repositorio:: Repositorio EIA .

Idioma:: eng

Description
Summary:	Since genetic engineering of humanized murine monoclonal antibodies was fi rst demonstrated over two decades ago, antibody engineering technologies have evolved based upon an increasing understanding of the mechanisms involved in antibody generation in vivo, and a constant search for alternative routes to evolve and exploit the characteristics of antibodies. As a result, antibody engineers have devised innovative strategies for the rapid evolution and selection of antibodies and novel antibody designs (i.e., antibody fragments). Phage display, cell display and ribosome display technologies, which comprise the core of the currently available technologies for the discovery and preparation of such antibodies, are reviewed herein. This article intends to communicate the state-of-the-art technology available for the engineering of antibodies to a general readership interested in this important fi eld. Therefore, important immunology concepts are introduced before detailed descriptions of the three antibody engineering technologies are presented in later sections. A comparison of these methodologies suggests that despite the predominance of phage display for the engineering of antibody fragments in the past 20 years, cell display and ribosome display will likely gain importance in the selection and discovery of the antibody fragments in the future. Finally, these technologies are likely to play an important role in the production of the next generation of antibody-based therapeutics.

Engineering antibody fragments: replicating the immune system and beyond

Publicaciones similares